在患有缺血性中风的患者中,MTHFR基因多态和H型高血压之间的关联
Bo Zhou1, Tingting Yang2, Shicang An3
1Postdoctoral Workstation, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, China.
PeerJ
|October 15, 2025
概括
MTHFR 677C>T TT基因型是缺血性中风患者H型高血压的独立风险因素. MTHFR C-A 单形提供保护,而 T-A 单形增加风险.
科学领域:
- 遗传学 是一个遗传学.
- 心血管疾病 心血管疾病
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 甲基酸酸减少酶 (MTHFR) 对于同类半氨酸的代谢至关重要.
- MTHFR多态性 (677C>T,1298A>C) 可能会损害酶活性,提高同类半氨酸水平.
- 高水平的同氨酸 (H型高血压) 与缺血性中风有关,但MTHFR在中风患者中高血压的作用尚不清楚.
研究的目的:
- 调查MTHFR基因多态和H型高血压之间的关联.
- 确定患有缺血性中风和高血压的患者中H型高血压的危险因素.
主要方法:
- 在215名患有高血压的缺血性中风患者中,MTHFR 677C>T和1298A>C多态的基因定型.
- 基因型和等位基因分布的分析,链接不平衡,和单位基因型的频率.
- 多变量后勤回归用于识别独立的风险因素.
主要成果:
- 在研究人群中,H型高血压是普遍存在的 (89.3%).
- 在H型高血压组中,MTHFR 677C>T TT基因型和T等位基因明显更频繁.
- TT基因型是一个独立的风险因素 (OR=2.615),而MTHFR C-A亚型是保护性的 (OR=0.485) 和T-A亚型是一个风险因素 (OR=2.029).
结论:
- 在患有缺血性中风的患者中,MTHFR 677C>T TT基因型是H型高血压的独立风险因素.
- 特定的MTHFR单元型 (C-A和T-A) 影响了这一群体中H型高血压的风险.
相关概念视频
01:29Hypertension II: Pathophysiology
787
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
787
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
467
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
467
01:18Hypertension and Regulation of Blood Pressure
3.7K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.7K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
401
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
401
01:28Hypertension I: Introduction
741
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
741
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319